Letaplimab represents a distinct medical strategy for addressing complement-mediated illnesses. This antibody targets complement component C1q, a key component of the complement cascade, aiming to block its initial https://deannahkeg874871.mpeblog.com/73614969/letaplimab-a-groundbreaking-therapeutic-strategy